Innovation Pharmaceuticals and U.S. Regional Biocontainment Laboratory Nearing Completion of Brilacidin Anti-SARS-CoV-2 (COVID-19) In Vitro Testing
?|?Source:?Innovation Pharmaceuticals Inc.
- Brilacidin is showing consistent and robust antiviral activity across the viral lifecycle in human lung and Vero cells; potential as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected
- Article to be submitted for peer-review publication in September, with pre-print made available